Targeted Protein Degraders | Global Pipeline

Last Update: Nov 25, 2022

Purchase the TPD database for this data in an Excel spreadsheet, plus added notes.


-
Company Status Candidate MOA/Platform Indications Stage Trial Trial Initiation Next milestone Milestone type
Bristol Myers SquibbPublicIberdomide IKZF1/3 molecular glue degraderMultiple myeloma (MM)IIINCT04975997July 2022--
Bristol Myers SquibbPublicCC-99282IKZF1/3 molecular glue degraderr/r NHLIINCT03930953May 2019--
ArvinasPublicBavdegalutamide (ARV-110)PROTAC targeting ARmCRPCIINCT03888612March 20192H23Initiate Ph3
Arvinas & PfizerPublicARV-471PROTAC targeting ERER+ HER2- metastatic BC (+- Ibrance)IINCT04072952Aug 2019--
Bristol Myers SquibbPublicCC-92480IKZF1/3 molecular glue degraderMMI/IINCT03989414Sep 2019--
Ranok TherapeuticsPrivateRNK05047BRD4-targeting protein degrader (chaperone-mediated)Advanced solid tumors or DLBCLI/IINCT05487170Aug 24 20222H23Preliminary data
C4 TherapeuticsPublicCFT7455IKZF1/3 molecular glue degraderr/r NHL or MMI/IINCT04756726June 20212022Topline data, R2PD
NovartisPublicDKY709IKZF2 molecular glue degraderAdvanced solid tumors (NSCLC, Melanoma, CRC, TNBC)I/IbNCT03891953May 2019--
Kangpu BiopharmaceuticalsPrivateKPG-818IKZF1/3 molecular glue degrader (lenalidomide analog)SLEIIaNCT04643067June 2022--
Bristol Myers SquibbPublicCC-90009GSPT1 molecular glue degraderAML (combo therapy)IbNCT04336982Aug 2020--
Bristol Myers SquibbPublicCC-94676PROTAC targeting ARmCRPCINCT04428788Jun 2020--
ArvinasPublicARV-766PROTAC targeting ARmCRPCINCT05067140Sep 20212H22Ph1 dose escalation data
Kymera Therapeutics & SanofiPublicKT-474IRAK4IL-1R/TLR-driven diseases (HS, AD)INCT04772885Feb 202114 Dec 22Ph1 HS and AD data
Nurix TherapeuticsPublicNX-2127PROTAC targeting BTK + IKZF1/3CLL, SLL, WM, MCL, MZL, FL, DLBCLINCT04830137May 2021Dec 2022Clinical update for CLL pts
Foghorn TherapeuticsPublicFHD-609BRD9 BiDAC degraderAdvanced synovial sarcoma, SMARCB1-deleted tumorsINCT04965753Aug 20212023Phase 1 data
Dialectic TherapeuticsPrivateDT2216PROTAC targeting BCL-XLr/r Solid tumors + Hematological malignanciesINCT04886622Oct 2021--
Bristol Myers SquibbPublicBMS-986397CK1α molecular glue degraderr/r AML, MDSINCT04951778Dec 2021--
Kangpu BiopharmaceuticalsPrivateKPG-818IKZF1/3 molecular glue degraderHematological malignanciesINCT04283097May 2020--
Kangpu BiopharmaceuticalsPrivateKPG-121CK1α molecular glue degradermCRPCINCT03569280Nov 2019--
Kymera TherapeuticsPublicKT-413PROTAC targeting IRAK4 + IKZF1/3MYD88-mutant tumorsINCT05233033June 2022Q422Data (safety, POM)
Kymera TherapeuticsPublicKT-333PROTAC targeting STAT3r/r NHL, PTCL, CTCL, LGL-L, Solid tumorsINCT05225584Jan 2022Q422Data
BioTheryXPrivateBTX-1188GSTP1 + IKZF1/3 molecular glue degraderHematological malignancies (NHL, AML), Solid tumorsINCT05144334Jan 2022YE22/Early 23Initial Ph1 data
C4 TherapeuticsPublicCFT8634BRD9 BiDAC degraderMetastatic SMARCB1-perturbed cancers, inc. synovial sarcoma and SMARCB1-null tumorsINCT05355753March 202217 NovPh1 data, 2022 CTOS meeting
Nurix TherapeuticsPublicNX-5948BTKCLL, SLL, DLBCL, FL, MCL, MZL, WM, PCNSLINCT05131022Apr 2022--
BioTheryXPrivateBTX-1188GSTP1 + IKZF1/3 molecular glueHematological malignancies (NHL, AML), Solid tumorsINCT05144334Jan 2022YE22/Early 23Ph1 data
Hinova PharmaceuticalsPrivateHP518PROTAC targeting ARmCRPCINCT05252364Feb 2022--
Palleon PharmaceuticalsPrivateE-602Sialidase (glycan degradation)OncologyINCT05259696Feb 2022--
Kintor PharmaceuticalPublicGT20029PROTAC targeting AR (topical formulation)Androgenic alopecia, Acne vulgarisINCT05428449Feb 2022--
Astellas PharmaPublicASP3082PROTAC targeting KRAS G12DAdvanced/metastatic r/r solid tumors with KRAS G12D mutationsINCT05382559Jun 2022--
Orum TherapeuticsPrivateORM-5029GSPT1 molecular glue degrader-anti-HER2 mAb (pertuzumab) conjugateHER2-expressing advanced solid tumorsINCT05511844Oct 2022--
Monte Rosa TherapeuticsPublicMRT-2359GSPT1 molecular glue degraderMyc-driven NSCLC, SCLC, DLBCL, high-grade neuroendocrine cancer, solid tumorsI/IINCT05546268Nov 2022--
Mission TherapeuticsPrivateMTX652USP30 deubiquitylating enzyme (USP30 inhibitor)CKD, IPFIND cleared---Initiate Phase 1
CullgenPrivateCG001419TRK degraderNTRK fusion-positive cancersIND cleared--Q422?Initiate Phase 1 in China
C4 TherapeuticsPublicCFT1946BRAF V600X degrader BRAF V600X driven cancers (melanoma, CRC, NSCLC)IND cleared--YE2022Initiate Ph1/2 trial
Prelude TherapeuticsPublicPRT3789SMARCA2 degraderSMARCA4-mutated NSCLC and other tumorsIND cleared--Q123First pt. dosing
C4 TherapeuticsPublicCFT8919EGFR L858R degrader BiDACDrug-resistant EGFR+ NSCLCIND-enabling--YE2022Complete preclin
Kymera TherapeuticsPublicKT-253PROTAC targeting MDM2Solid/liquid tumorsIND-enabling--2H22IND filing, present preclin data
Salarius PharmaceuticalsPrivateSP-3146Molecular glue degrader (S-enantiomer of avadomide)Hematological/solid tumorsIND-enabling--2023File IND, initiate Phase I
Captor TherapeuticsPrivateCPT-6281MCL-1 molecular glue degraderOncologyIND-enabling--2023File IND, initiate Phase I
Ubix TherapeuticsPrivateUBX-303PROTAC targeting BTKCLL, DLBCLIND-enabling----
PlexiumPrivate-IKZF2 molecular glue. Also has monovalent degraders.I-O combo with CPIsPreclin----
Roivant Sciences (Proteovant Therapeutics)Public-AR degraderProstate cancerPreclin----
Roivant Sciences (Proteovant Therapeutics)Public-STAT3 degraderOncology, ImmunologyPreclin----
Lycia TherapeuticsPrivate-Lysosomal (ASGPR) targeting chimera degraders-Preclin----
IDEAYA Biosciences & GSKPublic-Pol Theta protein degraderHRD+ tumorsPreclin--Q222Announce dev. candidate
ZenopharmPrivatePERD-101PROTAC targeting ERHR+/HER2- BCPreclin----
FIMECSPrivatePROTAC targeting IRAK-MImmuno-oncologyPreclin----
GluBio TherapeuticsPrivate-Molecular glue degraders, PROTACsHematological malignanciesPreclin----
Beactica TherapeuticsPrivateBEA-17LSD1 degrader, WRN, YAP-TEAD PROTACsOncology, MSI+ cancers, NF2-driven solid tumorsLeadOp----
CelerisTxPrivate-Novel TPDParkinson's, OncologyLeadOp----
Foghorn Therapeutics & LOXOPublic-Selective BRM degraderBRG1 mutated cancersHIt-lead--2023?Initiate IND-enabling studies
SyntheXPrivateSTX100NRAS, Cbl-b, Shoc2 molecular glue degraders-Hit validation----
Origami TherapeuticsPrivateORI-113Mutant HTT degraderHuntington's diseaseDisc----
ProgenraPrivate-PROTAC degraders of RTKs, KRAS & molecular gluesKRAS-driven cancers, neurodegenerative diseasesDisc----
Ribon TherapeuticsPrivateRBN012811PROTAC targeting PARP14-Disc----
Ascentage PharmaPublicAPG-265PROTAC targeting MDM2OncologyDisc----
PhoremostPrivatePM-006, PM-007PROTACs-Disc----
Amphista TherapeuticsPrivate-Novel TPD-Disc----
UbiquigentPrivate-PROTAC targeting DUB (USP1i)OncologyDisc----
UbiquigentPrivate-PROTAC targeting DUB (USP30)NeurodegenerationDisc----
ArvinasPublic-PROTAC targeting BCL6-Disc----
Monte Rosa TherapeuticsPublic-NEK7 MGDInflammatoryDisc----
AbbViePublic-Molecular glue degradersNeurological conditionsDisc----
AmgenPublic-Molecular glue degraders-Disc----
MerckPublic---Disc----
NeomorphPrivate-Molecular glue degradersOncologyDisc----
EvotecPublic-Molecular glue degradersNeurodegenerative conditionsDisc----
Seed Therapeutics (BeyondSpring subsidiary)Private-Molecular glue degradersNeurodegenerative, KRASG12DDisc---
Frontier MedicinesPrivate-Chemoproteomics/E3 ligase PROTACs-Disc----
Dunad TherapeuticsPrivate-Mono-valent degraders-Disc----
A2A PharmaPrivate-YAP-TEAD, KRAS degradersOncologyDisc----
Calico Labs (Alphabet subsidiary)Private--Diseases of aging (including Cancer)Disc----
BridgeBioPublic-GTP-KRAS degrader-Disc----
BiogenPublic-PROTACsNeurological (Alzheimer's, Parkinson's)Disc----
TRIANA BiomedicinesPrivate-Molecular glue degraders-Disc----
Janpix (Centessa Pharmaceuticals)Private-STAT3/5 monovalent degradersHematological malignanciesDisc----
GenerianPrivate-Degraders and stabilizers-Disc----
Schrodinger & Bristol Myers SquibbPublic-Protein degradersOncology, Immunology, NeurologyDisc----
Astex (Otsuka Pharmaceuticals)Public-PROTACs-R&D----
Avilar TherapeuticsPrivate-Extracellular/lysosomal (ASGPR) targeting chimeras-R&D----
Aurigene Discovery TechnologiesPrivate-ARv7, SMARCA2/4 degraders-R&D----
ProxygenPrivate-Molecular glue degraders-R&D----
NeomorphPrivate-Molecular glue degraders-R&D----
Xios TherapeuticsPrivate-PROTACsImmuno-oncologyR&D----
Kronos BioPublic-PROTACs-R&D----
Pin TherapeuticsPrivate-PROTACs, molecular glue degraders-R&D----
SitryxPrivate-PROTACs-R&D----
HotSpot TherapeuticsPrivate-PROTACs-R&D----
Casma TherapeuticsPrivate-Autophagy-dependent degradation-R&D----
UPPtheraPrivate-PROTACs, molecular glue degraders-R&D----
TriloPrivate-Novel TPD platform-R&D----
Autotac BioPrivate-Autophagy-targeting chimera-R&D----
Stablix TherapeuticsPrivate-Hetero-bifunctional small molecules to DEubiquitinylate proteins (stabilizers)CFR&D----
Cedilla TherapeuticsPrivate-Small molecule protein destabilizers OncologyR&D----
Almirall S.APublic-PROTACs, molecular glue degradersSevere immune-inflammatory skin diseasesR&D----
Boehringer IngelheimPrivate-PROTACs, molecular glues (w/ Proxygen)-R&D----
Orionis Biosciences BVPrivate-Molecular glue degraders-R&D----
Degron TherapeuticsPrivate-IKZF1/3 molecular glue degrader-R&D----
PAQ TherapeuticsPrivate-Autophagy-dependent degradation-R&D----
Vicinitas TherapeuticsPrivate-Deubiquitinase targeting chimera (PROTEIN STABILISER)-R&D----
Gluetacs TherapeuticsPrivate-PROTACs-R&D----
Innovo TherapeuticsPrivate-MGDs, PROTACs-R&D----
76BioPrivate---R&D----
Genentech (Roche)Public---R&D----
Vividion (Bayer)Public---R&D----
BioRap TechnologiesPrivate---R&D----
Blueprint MedicinesPublic---R&D----